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The crude and age-adjusted incidence rates of end-stage renal disease are estimated to be 151 and 232 per million population, respectively, in India.1 Chronic kidney 
disease in India is predominantly due to diabe-
tes mellitus and hypertension, as shown by data 
from the Indian CKD registry, comprising 36,000 
patients. The majority of the end-stage renal dis-
ease patients (>90%) in India and in other South 
Asian countries die within months of diagnosis, 
as renal replacement therapy is not affordable or 
not available.2 The rate of renal transplantations 
performed yearly in India translates to 3.25 per 
million population; the deceased-donation rate 
is 0.08 per million population per year.3 Since the 
promulgation of the Transplantation of Human 
Organs Act of 1994 (THOA), nongovernmental 
organizations in partnership with the state gov-
ernments have expanded the deceased-donor 
transplantation program. Organizing a nation-
wide deceased-donation program in India will 
always be a logistical challenge, as many towns 
and villages lack doctors and hospitals with infra-
structure for renal care. India spends 5.2% of its 
gross domestic product (US$1.237 trillion in 
2007) every year on health-care coverage, with 
only 0.9% coming from government contribution. 
There are regional disparities, with the southern 
and western regions of the country having bet-
ter industrial growth and literacy rates and better 
infrastructural support in the way of hospitals and 
doctors to support deceased-donor programs.
Current state of deceased-donor  
renal transplantation program
After the passage of THOA by the Indian par-
liament, the deceased-donation program was 
initially confined to half a dozen hospitals, with 
donation continuing in a sporadic manner, and 
since then has expanded to about 20 multi-
specialty hospitals with better infrastructure. The 
organs that were not used by the harvesting hos-
pitals were offered to other hospitals.4 In 1999, 
a meeting of six such hospitals that were regu-
larly doing deceased donations in Tamil Nadu 
was arranged by a nongovernmental organiza-
tion body called the Multi Organ Harvesting 
Aid Network (MOHAN), and the six hospitals 
decided to form a formal organ-sharing network 
in the country.5 A similar sharing network was 
started by the same nongovernmental organiza-
tion in the neighboring state of Andhra Pradesh 
in 2003 and employed grief counselors who could 
explore the possibility of organ donation. In both 
states MOHAN has facilitated the sharing of over 
400 deceased-donor organs. This is nearly one-
third of the total deceased transplants (about 
1400) done so far in India. The principles of the 
sharing network have been to not waste organs; 
to use them like a national resource; and to uti-
lize them anywhere in the country where there 
is a needy patient. This has resulted in organs 
being sent by flights to Delhi, Hyderabad, and 
Bangalore from Chennai when there were ‘no 
takers’ for livers or kidneys in the state. In the 
states of Gujarat and Maharashtra, more than 
300 deceased donations have taken place in the 
past 10 years. The Zonal Transplant Coordina-
tion Committee in Maharashtra has also evolved 
a sharing network for organs based on a patient 
point system. However, neither Maharashtra nor 
Gujarat share their organs with other neighbor-
ing states.
More recently, the Department of Health of 
the state government of Tamil Nadu decided 
to network all the 54 hospitals in its state that 
have a license for organ transplantation and to 
promote the deceased-donation program in the 
state. The four states of Tamil Nadu, Andhra 
Pradesh, Gujarat, and Maharashtra are leading 
in deceased organ donation, with a donation rate 
of 0.3 per million population in comparison with 
the national average of 0.08 per million popula-
tion.6 The government of Tamil Nadu regulated 
a program of deceased-donor transplantation 
for the first time by appointing a convener and 
producing a central registry for organ sharing 
(http://www.tnos.org). As of 2009 this initia-
tive has led, in a year, to the procurement of 140 
organs from 40 deceased persons; these organs 
were effectively shared through meaningful 
public–private partnership. The government-
run hospitals in the south have ensured access to 
deceased-donor organs to the poorest of the poor 
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free of cost through this network when the kid-
neys were transplanted in the government facility. 
The Ministry of Health and Family Welfare of the 
government of India has pledged US$160 million 
to establish organ procuring and transplant cent-
ers at the national, regional, and state levels to 
streamline organ transplantation in the country.
The overall potential of organ donation follow-
ing brain death in India is extremely high. The 
number of deaths due to road traffic accidents 
has increased in recent years and exceeds 110,000 
per year. It is estimated that 67% of such deaths 
occur due to brain death.7 In a recent monthly 
death audit of data of a government general 
hospital in Chennai, the number of patients 
with brain death was found to be more than 100 
(J.M., unpublished data). If the current dona-
tion rate were pushed from 0.08 to 1 per million 
population, it would provide all the livers, hearts, 
and lungs that are required in the country and 
to some extent satisfy the kidney shortage. It is 
highly probable that the four southern states will 
reach a deceased-donation rate of 1 per million 
population in the next two to three years, given 
the current organ donation rate.6 Most surveys 
done in India indicate a positive attitude toward 
organ donation. India is the birthplace of the 
major religions of Hinduism, Jainism, Sikhism, 
and Buddhism, and none of these religions has 
set a barrier to organ donation. A recent audit has 
shown one-year graft survival of 90% in the state 
of Tamil Nadu after deceased donation. Kidneys 
harvested from two cobra-bite victims were suc-
cessfully transplanted in four adult recipients—
three of them type 2 diabetics—in 1996 and 
1999 in Chennai. Two of the diabetic recipients 
survived for 16 and 22 months with functioning 
grafts, one patient was lost to follow-up after 2 
years, and the third recipient was alive and well 
13 years and 6 months after transplantation.
Shortcomings of deceased-donor transplantation
Grief counselors are not available in the major-
ity of the centers where counseling is needed 
for the families of brain death victims. Hence 
the doctors themselves may have to play the 
dual role of grief counselor and physician 
in charge of the patient. Presensitization is 
hardly ever assessed in patients on the waiting 
list for deceased-donor transplantation. The 
majority of the centers performing deceased-
donor transplant ation do not have facilities for 
cross-matching techniques in case of sensitized 
recipients, and a basic complement-dependent 
cytotoxicity is the laboratory tool for cross-
matching between the recipient and the donor. 
Because of transportation problems, recipi-
ents who are available in the vicinity or a short 
distance from the transplant center have bet-
ter access to deceased-donor transplantation 
compared with those living in the remote cor-
ners. Potentially life-saving induction agents 
such as interleukin-2 receptor antibodies and 
polyclonal antibodies are expensive, and hence 
the majority of the patients on the recipient list, 
who are self-paying, cannot afford them. Patients 
must bring upfront cash for hospitalization 
and management, as fewer than 15% have full 
reimbursement or insurance coverage. In a coun-
try where the living-donation program so far has 
been the accepted norm, a deceased-donation 
transplant often throws up challenges in early 
management of recipients with delayed graft 
function, dialysis, and prolonged hospital stay. 
Prospective recipients who are diabetic and have 
underlying coronary artery disease may not have 
had a chance to undergo full evaluation, and this 
is likely to increase morbidity and mortality in 
comparison with an elective live-donor trans-
plantation. Human leukocyte antigen matching 
for class I and class II antigens in order to avoid 
Table 1 | Price comparison of original and generic drugs available in the Indian market
Drug Introductory price (US$) Current price (US$) Generic price (US$)
Rituximab, 500 mg 1800 1200 1000
Mycophenolate mofetil, 500 mg 2.40 1.12 0.80
Daclizumab, 5 doses 3500 2500 None
Cyclosporine microemulsion, 100 mg None 2.20 1
Basiliximab, 2 doses 2880 2000 None
Everolimus, 0.25 mg None 1.44 None
Tacrolimus, 1 mg None None 0.54
Sirolimus, 1 mg 6.50 5 2
Equine anti-thymocyte globulin None 1700 800
Thymoglobulin, 25 mg 230 187 None
Valganciclovir, 450 mg 15 9.60 4.90
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mismatch is rarely performed because of time 
constraints and un availability of resources and 
facilities in certain centers.
Support from Indian pharmaceuticals and  
availability of immunosuppressive agents
The Indian pharmaceutical industry has shown 
robust growth in the past decade by manu-
facturing cheaper immunosuppressive agents 
that are not inferior in pharmacokinetics and 
pharmaco dynamics to the original brands. A 
cost comparison of the immunosuppressive 
agents is given in Table 1. This initiative by the 
Indian pharmaceutical industry has often forced 
the multi nationals that produce the brands of 
microemulsion forms of cyclosporine, tacrolimus, 
mycophenolate mofetil, and sirolimus to bring 
down their prices to withstand the competition. 
Immunosuppressive agents of Indian origin, 
because of their quality and low cost, are widely 
used in Africa, Latin America, Russia, and 
Eastern Europe in addition to Asia. Therapeutic 
drug monitoring is available in the major cities, 
and the results are provided within 24–48 hours. 
However, the cost of drug- level monitoring can 
be prohibitive (US$74.50 for sirolimus, US$15.50 
for tacrolimus, US$19.70 for cyclosporine), and 
hence it is limited in the tailoring of immuno-
suppressive agents. As a cost-effective measure, 
CYP3A4 inhibitors, including diltiazem and 
ketoconazole, are used to increase the blood levels 
and hence reduce the cost of immunosuppression. 
Immunosuppressive drugs are given free of cost 
in the state government-run hospitals in some 
southern states, such as Tamil Nadu.
Benefits in terms of good graft function, 
improved quality of life, reduced medical expenses 
for deceased-donor transplantation, and cheaper 
immunosuppressive agents have led to the offer-
ing of renal transplantation to a wider group of 
patients, thus avoiding selection bias depending 
on socioeconomic status.
DISCloSure
All the authors declared no competing interests. 
referenCeS
1. Modi GK, Jha V. The incidence of end-stage renal disease 
in India: a population-based study. Kidney Int 2006; 70: 
2131–2133.
2. Abraham G. The challenges of renal replacement therapy in 
Asia. Nat Clin Pract Nephrol 2008; 4: 643.
3. Khanna U. The economics of dialysis in India. Indian J Nephrol 
2009; 19: 1–4.
4. Mani MK. Development of cadaver renal transplantation in 
India. Nephrology 2002; 7: 177–182.
5. Shroff S, Navin S, Abraham G et al. Cadaver organ donation 
and transplantation: an Indian perspective. Transplant Proc 
2003; 35: 15–17.
6. Shroff S, Rao S, Kurian G et al. Organ donation and 
transplantation: the Chennai experience in India. Transplant 
Proc 2007; 39: 714–718.
7. Kumar A, Lalwani S, Agrawal D et al. Fatal road traffic 
accidents and their relationship with head injuries: an 
epidemiological survey of five years. Indian J Neurotrauma 
2008; 5: 63–67.
